Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
Kyverna Therapeutics
Kyverna Therapeutics is a company that is developing new therapies and cures for serious autoimmune diseases.
Sector
Subsector
Location
total rounds
total raised
Sonoma BioTherapeutics
Sonoma BioTherapeutics develops adoptive Treg therapies cell for autoimmune.
Sector
Subsector
Location
total rounds
total raised
Pandion Therapeutics
Pandion Therapeutics develops novel therapeutics for autoimmune diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Villaris Therapeutics
Villaris Therapeutics develops antibody therapeutics for vitiligo and autoimmune diseases.
Sector
Subsector
Location
Financials
Funding Rounds4
Number of Funding Rounds
Money Raised
Their latest funding was raised on 17.03.2021. Their latest round Post-IPO Equity
Flagship Pioneering
Flagship Pioneering creates and grows ventures to transform health and sustainability.
Sector
Subsector
Location
count Of Investments
count Of Exists
Flagship Pioneering
Flagship Pioneering creates and grows ventures to transform health and sustainability.
Sector
Subsector
Location
count Of Investments
count Of Exists
Co-Investors
Investors1
Number of lead investors
Number of investors
Flagship Pioneering
Flagship Pioneering creates and grows ventures to transform health and sustainability.
Sector
Subsector
Location
count Of Investments
count Of Exists
People
Founders2
Avak Kahvejian
Avak Kahvejian joined Flagship Ventures in 2011 as a Partner in VentureLabsTM, bringing nearly 7 years of operational experience in the biomedical tools space. Prior to Flagship, Avak was at Helicos BioSciences, a Flagship VentureLabsTM company which developed and commercialized the world's first single molecule sequencing technology. At Helicos since 2004, Avak held various business development, product management, marketing and sales roles. Most recently, as Vice President, Business Development for Helicos, he focused on establishing strategic partnerships in the areas of high-throughput sequencing and molecular diagnostics, leveraging the technology's unique capabilities. Avak earned his PhD from McGill University in the laboratory of Dr. Nahum Sonenberg, where his research focused on modulators of mRNA translation and their regulation. During his studies at McGill, Avak was awarded a Canadian Institutes of Health Research operating grant as a co-investigator to Dr. Sonenberg, and was selected for the Dean's Honour List upon graduation. At Flagship, Avak is developing new internally-generated ventures as part of VentureLabsTM and he is responsible for marketing and development firm-wide. Cygnal is a best-in-class team of biomedical experts and leaders collaborating to revolutionize how the world treats diseases.
current job
Avak Kahvejian
Noubar Afeyan
Noubar Afeyan is Founder, Senior Managing Partner and Chief Executive Officer at Flagship Ventures, a leading early stage venture capital firm. Noubar also leads the firm's VentureLabs unit that invents and launches transformative startups. Noubar is a Senior Lecturer at MIT’s Sloan School of Management where he has taught courses on technology-entrepreneurship, innovation and leadership since 2000. Noubar lectures widely in the United States and internationally on diverse topics ranging from entrepreneurship, innovation and venture capital to biological engineering, drug discovery, medical technologies and renewable energy. During his 28-year career as inventor, entrepreneur, CEO and venture capitalist, Noubar has co-founded and helped build over 35 successful life science and technology startups. Noubar was Founder and Chief Executive Officer at PerSeptive Biosystems, a leader in the bio-instrumentation field that grew to over $100M in annual sales within six years from its first sales. After PerSeptive's acquisition by Perkin Elmer/Applera Corporation in 1998, Noubar was Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of Celera Genomics. Currently Noubar serves on a number of public and private company boards including CiBO Technologies, Epiva BioSciences, Evelo BioSciences, Joule Unlimited, Kaleido BioSciences, Moderna Therapeutics, Pronutria Biosciences and Seres Therapeutics. Previously, Noubar was a Member of the founding team, Director and Investor in several highly successful ventures including Chemgenics Pharmaceuticals (acquired by Millennium Pharmaceuticals), Color Kinetics (acquired by Philips), Adnexus Therapeutics (acquired by Bristol-Myers Squibb) and Affinnova (acquired by AC Nielsen). Noubar received a Technology Pioneer 2012 award from the World Economic Forum in recognition of the breakthrough solar fuel technology being developed at Joule Unlimited. Noubar has served as Chairman of the Global Agenda Council on Chemicals, Advanced Materials and Biotechnology of the World Economic Forum as well as being a member of the Meta-Council on Emerging Technologies. Noubar is a Member of the Board of Overseers of the Boston Symphony Orchestra. In addition, he serves on the board of AmeriaBank and of UWC Dilijan International School, both of Armenia. Previously, Noubar was a Co-Founder and Member of the Board of Directors at National Competitiveness Foundation of Armenia, a private-public partnership dedicated to promoting economic development in the former Soviet Republic of Armenia. In 2008 Noubar received the Ellis Island Medal of Honor, an award granted to outstanding Americans who have distinguished themselves as United States citizens and who have enabled their ancestry groups to maintain their identities while becoming integral parts of American life. Noubar has authored numerous scientific publications and patents since earning his Ph.D. in Biochemical Engineering from MIT in 1987. Cygnal is a best-in-class team of biomedical experts and leaders collaborating to revolutionize how the world treats diseases.
current job
Noubar Afeyan
Employee Profiles46
Frederico Lourenco
Senior Director, Corporate Development and Strategy
Lili Wang
Associate director, analytical development
Ashley Case
Principal analyst quality control raw materials
Maiken Keson Brookes
Chief Legal Officer and Corporate Secretary
Alyssa Hoxie
Manager, benefits and human resources operations
Kristian Elverum
Senior vice president of business development and strategy